Q4 2025 Vericel Corp Earnings Call Transcript
Key Points
- Vericel Corp (VCEL) reported record fourth quarter revenue of $92.9 million, a 23% increase over the previous year.
- The company achieved a gross margin of nearly 80% and an adjusted EBITDA margin of 40% for the quarter.
- Vericel Corp (VCEL) ended the year with approximately $200 million in cash and investments and no debt.
- The MACI product line showed strong growth, with a 23% increase in revenue and record numbers of implants and biopsies.
- The company successfully expanded its MACI sales force and initiated the MACI Ankle clinical study, positioning for future growth.
- The guidance for 2026 implies a slight decrease in growth rate compared to previous expectations, with MACI revenue growth projected at around 18% at the midpoint.
- There is uncertainty regarding the potential BARDA award for NexoBrid, which is not included in the initial revenue guidance.
- The company faces increased operating expenses due to the sales force expansion and new facility costs.
- Gross margin guidance for 2026 is set at 75%, slightly lower than the 79% achieved in Q4 2025, due to additional costs from the new manufacturing facility.
- The MACI Arthro launch, while successful, requires ongoing investment and development to maintain momentum and improve conversion rates.
Please stand by. We are about to begin. Good day, and welcome to the Vericel Corporation Fourth Quarter 2025 Earnings Call. Today's call is being recorded.
At this time, I'd like to turn the call over to Eric Burns, Vericel's Vice President of Finance and Investor Relations. Please go ahead, sir.
Thank you, operator, and good morning, everyone. Joining me on today's call are Vericel's President and Chief Executive Officer, Nick Colangelo; and our Chief Financial Officer, Joe Mara.
Before we begin, let me remind you that on today's call, we will be making forward-looking statements covered under the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from expectations and are described more fully in our filings with the SEC. In addition, all forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
